US Patent

US12364700 — Medical use of pharmaceutical combination or composition

Method of Use · Assigned to Boehringer Ingelheim International GmbH · Expires 2037-06-08 · 11y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the medical use of a DPP-4 inhibitor in combination with metformin for patients with chronic kidney disease.

USPTO Abstract

The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4224 — Jardiance
U-4224 — Jardiance
U-4224 — Tradjenta
U-4224 — Tradjenta
U-4224 — Tradjenta
U-4224 — Jardiance
U-4224 — Tradjenta
U-4224 — Tradjenta
U-4224 — Tradjenta
U-4224 — Jardiance
U-4224 — Jardiance
U-4224 — Jardiance

Patent Metadata

Patent number
US12364700
Jurisdiction
US
Classification
Method of Use
Expires
2037-06-08
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.